Market Overview

The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO

The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO

Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front and fairly positive results reported by pharma giant Johnson & Johnson (NYSE: JNJ).

Equillium Inc (NASDAQ: EQ) was among the biggest gainers of the week after a drug that it licensed from Biocon was granted emergency use authorization in India for treating cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

Moderna Inc (NASDAQ: MRNA) advanced in all five sessions of the week, with detailed interim Phase 1 data publication, positive sell-side commentary and news of inclusion in the Nasdaq 100 Index serving as catalysts.

The following are key catalysts in the unfolding week.


Galactosemia Foundation 2020 Virtual Conference, July 17-19


The FDA is set to rule on Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ) NDA for JZP-258, which is being evaluated as a treatment option for cataplexy —excessive daytime sleepiness — in patients 7 and older with narcolepsy.


  • Biogen Inc (NASDAQ: BIIB) (Wednesday, before the market open)
  • Quest Diagnostics Inc (NYSE: DGX) (Thursday, before the market open)
  • West Pharmaceutical Services Inc. (NYSE: WST) (Thursday, before the market open)
  • Edwards Lifesciences Corp (NYSE: EW) (Thursday, after the close)
  • LeMaitre Vascular Inc (NASDAQ: LMAT) (Thursday, after the close)


ACell, a regenerative medicines company that develops products designed to facilitate the body's ability to repair and remodel tissue, is planning a 5-million-share IPO at an estimated price range of $14-$16. The company has applied for listing its shares on the Nasdaq under the ticker symbol "ACLL."

IPO Quiet Period Expirations

  • Polypid Ltd (NASDAQ: PYPD)
  • Akouos Inc (NASDAQ: AKUS)
  • Fusion Pharmaceuticals Inc (NASDAQ: FUSN)
  • ADiTx Therapeutics Inc (NASDAQ: ADTX)

Related Links:

Researchers Say AbbVie's Tricor Reduced Severity Of COVID-19 Into 'Nothing Worse Than A Common Cold'

4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock


Related Articles (JAZZ)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Penny Stocks Previews FDA Top Stories Trading Ideas Best of Benzinga